Cervical Cancer Diagnostic Market Introduction and Overview
According to SPER Market Research, the Global Cervical Cancer Diagnostic Market is estimated to reach USD 13.37 billion by 2033 with a CAGR of 5.28%.
The report includes an in-depth analysis of the Global Cervical Cancer Diagnostic Market, including market size and trends, product mix, Applications, and supplier analysis. Cervical cancer is a form of cancer that develops in the cervix. The narrower, lower end of the uterus is called the cervix (womb). The uterus and vagina are joined by the cervix. Usually, it progresses gradually over time. Before cervical cancer manifests itself, dysplasia occurs in the cervix's cells. It starts to show abnormal cells in the cervical tissue. If the abnormal cells are not eliminated or killed over time, they may develop into cancerous cells and begin to proliferate and spread more into the cervix and adjacent tissues. Finding precancerous cervical cell alterations is the aim of cervical cancer screening, as treatment can stop cervical cancer from developing in these cases.
- The World Health Organization published updated recommendations for cervical cancer screening and care in July 2021. The revised guidelines state that screening for women in the general public should start at age thirty. Every five to ten years, routine screening with a validated HPV test is recommended. However, screening for HIV should begin at age 25 and be repeated every three to five years for women who are living with the virus. HPV DNA testing can be applied as a stand-alone test or in conjunction with other screening techniques to treat the infection. Based on the most recent data regarding the efficacy of cervical cancer screening and treatment, these new recommendations have been made. Their goal is to make them more affordable and available to women worldwide.
- Low-cost DNA testing for HPV infections may increase access to cervical cancer screening, according to a June 23, 2023, LabMedica report. Bioengineers at Rice University have created an inexpensive point-of-care DNA test for HPV infections. The test may increase access to cervical cancer screening in low- and middle-income nations, where the illness claims the lives of over 300,000 women annually.
- F. Hoffmann-La Roche Ltd., a multinational healthcare business based in Switzerland, declared in June 2022 that a “human papillomavirus (HPV) self-sampling solution†would be made available in territories that accept the CE mark. The primary use of this test kit is for HPV screening, which identifies women who may be at risk of cervical cancer.
Market Opportunities and Challenges
Cervical cancer diagnostics have a large market opportunity because to the growing awareness of the value of HPV vaccination and screening programs. The primary risk factor for cervical cancer is HPV infection, which is what HPV vaccination programs seek to avoid. The incidence of cervical cancer can be further decreased by combining successful screening programs with HPV vaccination campaigns, which will also create a long-term market for diagnostic tools. For cervical cancer to be prevented and identified at an early stage, screening is essential. Screening for cervical cancer typically entails Pap tests, HPV tests, or a combination of the two. Healthcare providers can improve the efficacy of their cervical cancer prevention strategies by coordinating HPV vaccination programs with routine screening programs. This may lead to a decline in the incidence of cervical cancer and a rise in the market for diagnostic tools including colposcopes, Pap tests, and HPV tests. Moreover, the cost of treating cervical cancer can be decreased with the combination of HPV vaccine and screening programs.
The accuracy of cervical cancer screening tests is critical for recognizing the disease early and delivering appropriate therapy. The likelihood that patients will survive is significantly affected by this. These tests may miss precancerous or early-stage cancerous lesions if they are not sensitive enough, which could delay diagnosis and reduce the likelihood of an effective course of therapy. However, if the tests are not specific enough, they can falsely diagnose non-cancerous diseases as cancer, which would force patients to undergo invasive and needless surgeries that would be emotionally upsetting. There are a number of reasons why the accuracy of some tests for cervical cancer diagnosis may be compromised. One reason for this is that cervical cancer can be hard to identify with these tests since it can be hard to find the disease in its early stages. The fact that a variety of factors, including age, activity level, and general health, can have an impact on cervical cancer adds to the limited accuracy of these tests. Because of this, a test's accuracy can change based on the patient and their unique situation.
Market Competitive Landscape
There are a number of significant businesses in the competitive and fragmented cervical cancer diagnostic industry. Zilico, Siemens Healthineers AG, QIAGEN NV, Abbott Laboratories, Becton, Dickinson and Co, Quest Diagnostics Inc, F. Hoffmann-La Roche Ltd, Guided Therapeutics, Hologic Inc, and Bio-Rad Laboratories are a few of the top companies in the sector.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Diagnostic Test, By Age Group, By End User
|
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
|
| Companies Covered | Zilico, Siemens Healthineers AG, QIAGEN NV, Abbott Laboratories, Becton, Dickinson and Co, Quest Diagnostics Inc, F. Hoffmann-La Roche Ltd, Guided Therapeutics, Hologic Inc, Bio-Rad Laboratories.
|
COVID-19 Impact on Global Cervical Cancer Diagnostic Market
The COVID-19 pandemic in 2020 had a big effect on the market. The disruptions in healthcare services following the COVID-19 epidemic presented hurdles for the cervical cancer diagnostics market. Diagnostics for cervical cancer declined as a result of the emphasis on managing COVID-19 cases. The number of women undergoing routine testing was impacted by the postponement of non-urgent operations and screenings by numerous healthcare facilities. Further lowering screening rates were mobility limitations and concerns about catching the virus in medical settings. Financial hardships for patients and healthcare providers resulted from the pandemic's economic effects on healthcare budgets. This might have had a negative impact on the need for pricey diagnostic procedures.
Key Target Audience:
- Healthcare Providers
- Gynecologists and obstetricians
- Pathologists
- Government Health agencies and policymakers
- Medical Laboratories
- Research institutions
Our in-depth analysis of the Cervical Cancer Diagnostic Market includes the following segments:
|
By Diagnostic Test: |
Pap Smear Tests
HPV Test
Biopsy and ECC
Colposcopy Tests
Others
|
|
By Age Group: |
20 to 40 years
above 40 years
|
|
By Vertical: |
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers
Diagnostic Centers
Others
|
Key Topics Covered in the Report:
- Global Cervical Cancer Diagnostic Market Size (FY’2024-FY’2033)
- Overview of Global Cervical Cancer Diagnostic Market
- Segmentation of Global Cervical Cancer Diagnostic Market By Diagnostic Test (Pap Smear Tests, HPV Test, Biopsy and ECC, Colposcopy Tests, Others)
- Segmentation of Global Cervical Cancer Diagnostic Market By Age Group (20 to 40 years, above 40 years)
- Segmentation of Global Cervical Cancer Diagnostic Market By End User (Hospitals, Speciality Clinics, Cancer and Radiation Therapy Centers, Diagnostic Centers, Others)
- Statistical Snap of Global Cervical Cancer Diagnostic Market
- Expansion Analysis of Global Cervical Cancer Diagnostic Market
- Problems and Obstacles in Global Cervical Cancer Diagnostic Market
- Competitive Landscape in the Global Cervical Cancer Diagnostic Market
- Impact of COVID-19 and Demonetization on Global Cervical Cancer Diagnostic Market
- Details on Current Investment in Global Cervical Cancer Diagnostic Market
- Competitive Analysis of Global Cervical Cancer Diagnostic Market
- Prominent Players in the Global Cervical Cancer Diagnostic Market
- SWOT Analysis of Global Cervical Cancer Diagnostic Market
- Global Cervical Cancer Diagnostic Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Cervical Cancer Diagnostic Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Cervical Cancer Diagnostic Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cervical Cancer Diagnostic Market
7. Global Cervical Cancer Diagnostic Market, By Diagnostic Test (USD Million) 2020-2033
7.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2020-2026
7.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2027-2033
7.3. Pap Smear Tests
7.4. HPV Test
7.5. Biopsy and ECC
7.6. Colposcopy Tests
7.7. Others
8. Global Cervical Cancer Diagnostic Market, By Age Group (USD Million) 2020-2033
8.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2020-2026
8.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2027-2033
8.3. 20 to 40 years
8.4. above 40 years
9. Global Cervical Cancer Diagnostic Market, By End User (USD Million) 2020-2033
9.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Specialty Clinics
9.5. Cancer and Radiation Therapy Centers
9.6. Diagnostic Centers
9.7. Others
10. Global Cervical Cancer Diagnostic Market Forecast, 2020-2033 (USD Million)
10.1. Global Cervical Cancer Diagnostic Market Size and Market Share
11. Global Cervical Cancer Diagnostic Market, By Region, 2020-2033 (USD Million)
11.1. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2020-2026)
11.2. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Zilico
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Siemens Healthineers AG
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. QIAGEN NV
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Abbott Laboratories
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Becton, Dickinson and Co.
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Quest Diagnostics Inc.
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. F. Hoffmann-La Roche Ltd.
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Guided Therapeutics
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Hologic Inc.
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Bio-Rad Laboratories Inc.
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. List of Abbreviations
14. Reference Links
15. Conclusion
16. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
